Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues
- PMID: 26245716
- PMCID: PMC4530473
- DOI: 10.1038/ncomms8808
Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues
Erratum in
-
Corrigendum: Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues.Nat Commun. 2016 Dec 8;7:13775. doi: 10.1038/ncomms13775. Nat Commun. 2016. PMID: 27929114 Free PMC article. No abstract available.
Abstract
Marrow adipose tissue (MAT) accumulates in diverse clinical conditions but remains poorly understood. Here we show region-specific variation in MAT adipocyte development, regulation, size, lipid composition, gene expression and genetic determinants. Early MAT formation in mice is conserved, whereas later development is strain dependent. Proximal, but not distal tibial, MAT is lost with 21-day cold exposure. Rat MAT adipocytes from distal sites have an increased proportion of monounsaturated fatty acids and expression of Scd1/Scd2, Cebpa and Cebpb. Humans also have increased distal marrow fat unsaturation. We define proximal 'regulated' MAT (rMAT) as single adipocytes interspersed with active haematopoiesis, whereas distal 'constitutive' MAT (cMAT) has low haematopoiesis, contains larger adipocytes, develops earlier and remains preserved upon systemic challenges. Loss of rMAT occurs in mice with congenital generalized lipodystrophy type 4, whereas both rMAT and cMAT are preserved in mice with congenital generalized lipodystrophy type 3. Consideration of these MAT subpopulations may be important for future studies linking MAT to bone biology, haematopoiesis and whole-body metabolism.
Conflict of interest statement
O.A.M. holds stock in MRK and ESRX, and has received research funding from Eli Lilly and Company. W.P.C. received fellowship funding from Eli Lilly and Company. E.L.S. and O.A.M. have received research funding from Biomet Biologics. A.K. has received research funding from Rhythm Pharmaceuticals. The remaining authors declare no competing financial interests.
Figures
References
-
- Botolin S. & McCabe L. R. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J. Cell. Physiol. 209, 967–976 (2006). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01-DK097708/DK/NIDDK NIH HHS/United States
- P30 DK040561/DK/NIDDK NIH HHS/United States
- R24 DK092759/DK/NIDDK NIH HHS/United States
- S10 RR026336/RR/NCRR NIH HHS/United States
- R24-DK092759/DK/NIDDK NIH HHS/United States
- S10-RR026336/RR/NCRR NIH HHS/United States
- R56 AR044927/AR/NIAMS NIH HHS/United States
- R01 AR044927/AR/NIAMS NIH HHS/United States
- K99-DE024178/DE/NIDCR NIH HHS/United States
- R01 DK097708/DK/NIDDK NIH HHS/United States
- AR44927/AR/NIAMS NIH HHS/United States
- K23 DK094820/DK/NIDDK NIH HHS/United States
- P30 DK089503/DK/NIDDK NIH HHS/United States
- P30-DK089503/DK/NIDDK NIH HHS/United States
- K23-DK094820/DK/NIDDK NIH HHS/United States
- R29 AR044927/AR/NIAMS NIH HHS/United States
- K99 DE024178/DE/NIDCR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
